Table 4 Loncastuximab Monotherapy Outcomes.
Loncastuximab line of therapy | ||
|---|---|---|
3rd Line N = 95 (%) | 4th Line N = 23 (%) | |
Overall response rate | 69 (73%) | 18 (78%) |
Best overall response | ||
Complete response | 32 (34%) | 4 (17%) |
Partial response | 37 (39%) | 14 (61%) |
Stable disease | 18 (19%) | 3 (13%) |
Progressive disease | 4 (4%) | 2 (9%) |
Death | 4 (4%) | 0 (0%) |
Duration of response | ||
Median (95% CI) | NR (8, NR) | 7.6 (6.0, 8.9) |
12-month DOR, (%) | 68% | 22% |
Progression-free survival | ||
Median (95% CI) | NR | 12.0 (8.1, 12.0) |
12-month PFS, (%) | 77% | 27% |
24-month PFS, (%) | NR | 22% |
Overall survival | ||
Median (95% CI) | NR | NR (19.3, NR) |
12-month OS, (%) | 84% | 95% |
24-month OS, (%) | 79% | 64% |
